
LXEO Stock Forecast & Price Target
LXEO Analyst Ratings
Bulls say
Lexeo Therapeutics Inc. focuses on innovative gene therapies for hereditary and acquired diseases, catering to significant unmet medical needs, which positions the company favorably in the biopharmaceutical market. Improved clinical outcomes have been observed, with high-dose patients showing notable mean enhancements of approximately 22% in non-sustained ventricular tachycardia (NSVT) and around 14% in premature ventricular contractions (PVCs), indicating the potential efficacy of its treatments. Additionally, the anticipated regulatory alignment and the increasing patient referrals to specialized centers following therapy advancements further support a favorable long-term outlook for Lexeo Therapeutics.
Bears say
The negative outlook on Lexeo Therapeutics's stock is primarily driven by concerns regarding the reproducibility of early activity data in subsequent clinical trials, which may result in lower-than-expected functional benefits or the emergence of safety signals. Additionally, potential changes in regulatory guidance surrounding trial design, including factors such as sample size and endpoints, could lead to delays, further impacting the company's ability to progress its gene therapies. As a result, these factors collectively raise the risk of downward revisions to the company's price target.
This aggregate rating is based on analysts' research of Lexeo Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
LXEO Analyst Forecast & Price Prediction
Start investing in LXEO
Order type
Buy in
Order amount
Est. shares
0 shares